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Abstract
Human papillomaviruses (HPV) cause a variety of mucosal and skin lesions ranging from benign proliferations to invasive
carcinomas. The clinical manifestations of infection are determined by host-related factors that define the natural anti-HPV
barrier. Key elements of this barrier are the EVER1 and EVER2 proteins, as deficiency in either one of the EVER proteins leads
to Epidermodysplasia Verruciformis (EV), a genodermatosis associated with HPV-induced skin carcinoma. Although EVERs
have been shown to regulate zinc homeostasis in keratinocytes, their expression and function in other cell types that may
participate to the anti-HPV barrier remain to be investigated. In this work, we demonstrate that EVER genes are expressed in
different tissues, and most notably in lymphocytes. Interestingly, in contrast to the skin, where EVER2 transcripts are hardly
detectable, EVER genes are both abundantly expressed in murine and human T cells. Activation of CD4+ and CD8+ T cells via
the TCR triggers a rapid and profound decrease in EVER expression, accompanied by an accumulation of free Zn
2+ ions.
Thus, EVER proteins may be involved in the regulation of cellular zinc homeostasis in lymphocytes. Consistent with this
hypothesis, we show that the concentration of Zn
2+ ions is elevated in lymphoblastoid cells or primary T cells from EVER2-
deficient patients. Interestingly, we also show that Zn
2+ excess blocks T-cell activation and proliferation. Therefore, EVER
proteins appear as key components of the activation-dependent regulation of Zn
2+ concentration in T cells. However, the
impact of EVER-deficiency in T cells on EV pathogenesis remains to be elucidated.
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Introduction
Papillomaviruses are widespread infectious agents, transmitted
by sexual or cutaneous contacts. Human papillomaviruses (HPV)
cause a variety of mucosal and skin lesions, ranging from clinically
unapparent and benign proliferations such as warts, papillomas or
condylomas, to fully invasive cervical or skin carcinomas. A crucial
role in determining the clinical outcome of a given HPV infection
is played by host-related factors [1,2]. Notably, the majority of
HPV-induced lesions (both skin and mucosal) are spontaneously
cleared. In some cases the virus is not eradicated, leading to
persistent lesions that may evolve to invasive carcinoma [2]. The
nature of this host-virus interplay is largely unknown, but it has
been proposed that ill-defined host derived factors could form a
natural anti-HPV barrier [3,4]. This concept is supported by the
existence of Epidermodysplasia Verruciformis (EV), a rare human
genetic disease associated with exquisite sensitivity to papilloma-
viruses belonging to the beta genus (ß-HPVs) [4–6]. EV-suffering
patients display a defect in the natural anti-HPV barrier, leading
to life-long persistence of skin HPV infections and consequently to
the development of diverse epidermal lesions, including skin
carcinoma induced by HPV5. The mechanism of this unusual
vulnerability to HPV in EV patients and the nature of the
deficiency of the anti-HPV barrier remain uncertain. However, we
have previously demonstrated that loss-of-function mutations in
either of two genes (EVER1/TMC6 or EVER2/TMC8) are
responsible for the majority of EV cases [7–10]. Recently, we
have also shown that EVER1/TMC6 and EVER2/TMC8
proteins are located in the endoplasmic reticulum of keratinocytes,
where they form a complex with zinc transporter-1 (ZnT-1),
thereby controlling the cellular zinc balance [11].
The concentration of free zinc ions in the cell is extremely small,
in the low nanomolar range. As HPV E6 and E7 are zinc-binding
proteins, it has been hypothesized that EVER could directly
control virus life cycle in keratinocytes by limiting accessibility of
free Zn
2+ ions. Nevertheless, Zn
2+ ions can influence numerous
signal transduction pathways, in different cell types [12–14], and
zinc imbalance could have, potentially, much broader effects.
Based on preliminary transcriptome analyses [15], EVER might be
ubiquitously expressed, suggesting that its expression in cells other
than keratinocytes could contribute to the anti-HPV barrier.
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defect in the natural anti-HPV barrier in EV patients is not limited
to epidermis but may potentially involve the adaptive immune
system [5]. Notably, EV patients consistently exhibit immune
abnormalities, mainly related to defective cell-mediated responses
[6,16]. The responses to HPV antigens and common skin
sensitizers (e.g., dinitrochlorobenzene) are compromised in EV
patients [16–18]. Moreover, EV-like skin eruptions associated with
HPV have been only in some instances reported in severely
immunocompromised patients, pointing to the involvement of
very specific mechanisms in the control of ß-HPVs [19–23].
The causes of the immunological defects in EV remain
controversial [6,10]. They could be directly due to the impact of
EVER-deficiency in immune cells or secondary to the massive life-
long HPV skin infection [24]. Therefore, we decided to assess the
expression and function of EVERs in lymphocytes.
Results and Discussion
We first analyzed the expression of EVER genes in a panel of
freshly collected murine tissues, and in murine and human
lymphocyte subsets. Using both classical RT-PCR (data not
shown) and quantitative RT-PCR (qRT-PCR), we observed that
EVER1 and EVER2 were clearly expressed in spleen and thymus
(Fig. 1A), as well as in purified murine (Fig. 1B) and human (Fig.
S1A, B) lymphocyte populations. EVER1, and to a lesser extent
EVER2, were also expressed in brain, heart, kidney, liver and skin
(Fig. 1A). The identity of the amplified bands was confirmed by
direct sequencing of the RT-PCR products or by cloning and
sequencing of the qRT-PCR products (data not shown). It is
noteworthy that the highest expression of EVER1 and EVER2
genes was not found in the skin but rather in lymphoid organs
(Fig. 1A). The expression of EVER1 and EVER2 did not differ
significantly between B and T cells (Fig. 1B), or between CD8+
and CD4+ T cells (Fig. 1B, Fig. S1B). Moreover, the amount of
EVER1 and EVER2 transcripts, as assessed by qRT-PCR, was
similar in CD8+ and CD4+ T cell subsets. The mean EVER2/
EVER1 expression ratio was 0.96 (n=4) and 0.77 (n=6) in CD8+
and CD4+ T cells, respectively. Interestingly, a strikingly different
pattern of EVER gene expression was observed in the skin where
EVER1 was preferentially expressed whereas EVER2 was barely
detectable (mean EVER2/EVER1 expression ratio 0.07; n=3).
EVER1- or EVER2-deficiency leads to a clinically identical EV
phenotype in humans [7–9]. This observation has two important
implications. First, it suggests that EVER1 and EVER2 have non-
redundant functions. Indeed, the absence of either one of the
EVER proteins leads to the dysfunction of the whole EVER
complex resulting in zinc imbalance [11]. Second, the cell type(s)/
tissue(s) where both genes are expressed, and not those with a
selective expression of either EVER1 or EVER2, are most
probably essential in EV pathogenesis. In this context, it is
tempting to speculate that the lymphoid tissue, which is
characterized by a high expression of both EVER1 and EVER2
genes, rather than the skin, where the constitutive expression of
EVER2 is extremely low (Fig. 1A), could be most relevant to EV
pathogenesis.
We next verified by western blot that EVER proteins were
expressed in spleen and freshly purified CD4+ or CD8+ T cells. A
single band of approximately 100 kDa was detected using a
commercially available antibody against murine EVER1 (Fig. 1C,
D). To ensure that the antibody used was specific, and that it could
discriminate between the two related EVER1 and EVER2
proteins, we employed two complementary strategies. First, the
expression of EVER1 was confirmed with a second antibody
recognizing a distinct epitope of EVER1 (Osenses; OSR00223W).
A single band of approximately 100 kDa was detected with this
antibody in spleen and in CD8+ T cell lysates (data not shown).
Second, we tested whether these two anti-EVER1 antibodies
specifically recognized EVER1. To this end, 293 T cells were
transfected with plasmids encoding either EVER1-FLAG or
EVER2-FLAG fusion proteins. The fusion proteins were subse-
quently precipitated using the anti-FLAG antibody and western
blot analyses were performed. We were able to detect both
EVER1-FLAG and EVER2-FLAG fusion proteins with the anti-
FLAG antibody. However, the two anti-EVER1 antibodies
recognized a single band (corresponding to MW < 85 kDa) in
cells expressing EVER1-FLAG, but not in cells expressing
EVER2-FLAG (Fig. 1E), demonstrating their specificity. We
attempted to verify by the same approach the expression of the
EVER2 protein in T cells but the anti-EVER2 antibody tested
(Abcam, ab70002) did not work in our hands (data not shown).
Since EVER proteins form a complex with ZnT-1 [4,11], a
well-characterized zinc transporter whose expression is enhanced
by Zn
2+ ions through the MTF-1 transcription factor [25,26], we
evaluated whether transcription of EVER1 and EVER2 in T cells
could also be regulated by zinc. Whereas expression of two zinc-
inducible genes (MT-2 and ZnT-1) was clearly increased 2 or 6
hours after exposition to a non-toxic concentration of zinc
(100 mM), expression of EVER genes remained stable following
6- and even 24-hour exposition to zinc (Fig. 2A).
We next tested the impact of in vitro T-cell activation and
differentiation on EVER expression. EVER1 and EVER2 were
constitutively expressed in purified naive CD8+ (Fig. 2B) and
CD4+ (Fig. 2C) T cells. Interestingly, activation of these T cells
using anti-CD3 and anti-CD28 antibodies led to a rapid and
profound decrease in EVER1 and EVER2 mRNA levels. The drop
in EVER1 and EVER2 expression was detected as early as 3 hours
after activation (Fig. 2B, C). This decreased expression of EVER
genes was maintained for at least 3 days (Fig. 2B, C). A similar
EVER1 and EVER2 mRNA down-regulation was found in human
T cells following TCR/CD28–dependent activation (Fig. S2A, B).
The TCR and CD28 exerted a synergistic effect on the down-
modulation of EVER genes, as triggering of either TCR or CD28
alone had little or no effect (Fig. 2D). We then validated these data
in an antigen-driven T-cell activation system, using naive CD8+ T
cells specific for an influenza virus hemagglutinin peptide (HA512–
520; IYSTVASSL), originating from CL4-TCR transgenic mice
[27,28]. Activation of purified TCR-transgenic CD8+ T cells with
syngeneic antigen-presenting cells loaded with the cognate HA512–
520 peptide was also associated with a clear and long-lasting
decrease in the expression of both EVER genes (Fig. 2E).
The exact mechanism of the down-regulation of EVER
expression in response to T-cell activation remains unknown.
Interestingly, the reduction in the amount of EVER transcripts is
rapid, suggesting that EVER mRNA might be relatively unstable.
Probably, due to its rapid turnover, the suppression of the
transcription of the corresponding gene would result in such a
rapid reduction in the mRNA quantity. Regardless of the exact
molecular basis of this observation, the role of EVER1 and
EVER2 in T cells and the functional significance of the
modulation of their expression constitute an important unan-
swered question.
Cellular zinc homeostasis is tightly controlled by an elaborate
system composed of different zinc sensors (like MTF-1), trans-
porters (ZnT and ZIP families), and buffering proteins such as
metallothioneins [29]. It has been suggested that ZnT-1 and the
EVER/ZnT-1 complex, like the other members of the ZnT
family, could be involved in the transport of Zn
2+ ions out of the
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2+ cytoplasmic level in
spite of the large gradient of this metal across the plasma
membrane [4,11,29]. Based on our data, we propose that the
EVER complex is involved in the regulation of zinc balance in T
cells, and that down-modulation of the EVER expression during T-
cell activation could impact zinc homeostasis. In the course of
CD8+ and CD4+ T-cell activation, we observed a decreased
expression of EVER1 and EVER2 as well as of ZnT-1 (data not
shown), with concomitant up-regulation of ZIP10 (Fig. 3A, B) and
ZIP6 (Fig. S3A, B) expression. ZIP10 and ZIP6 are plasma
membrane transporters responsible for Zn
2+ influx into the cell,
and in particular in T cells [30,31]. This coordinated reorgani-
zation of zinc transporter expression is compatible with a program
of zinc accumulation in the cytosol of activated T cells. Indeed, we
confirmed that the total amount of free Zn
2+ ions per cell was
significantly increased 24 h after TCR- and CD28-dependent
Figure 1. EVER1 and EVER2 are expressed in lymphocytes. A. Expression of EVER1 and EVER2 genes in different mouse organs was assessed by
qRT-PCR. Expression in the spleen was set as 100%. For each organ at least 3 independent experiments were performed. B. Expression of EVER1 and
EVER2 genes in murine T and B cells was determined by qRT-PCR. At least 3 independent experiments were performed for each cell type. Expression
of EVER1 protein in murine splenocytes (C) and purified T cells (D) was determined by western blot. An EVER1-specific antibody (Abcam; ab67326)
was used. A single band at <100 kDa was detected (predicted EVER1 MW=91 kDa). E. 293 T cells were transfected with plasmids encoding either
EVER1-FLAG or EVER2-FLAG fusion protein. The fusion protein was immunoprecipitated with anti-FLAG antibody and subsequently a western-blot
was performed using the anti-FLAG antibody or two different anti-EVER1 antibodies (Ab n
o1 - Abcam; ab67326; Ab nu2 - Osenses; OSR00223W).
doi:10.1371/journal.pone.0039995.g001
Figure 2. EVER1 and EVER2 expression is strongly down-regulated in T cells following TCR-mediated activation. A. Purified murine
naive CD8+ T cells were incubated in 100 mM zinc for the indicated period of time. Thereafter the expression of metallothionein 2 (MT-2), zinc
transporter 1 (ZnT-1) as well as EVER1 and EVER2 was assessed by qRT-PCR. Data are from 3 independent experiments. Purified murine naive CD8+ T
cells (B) or CD4+ T cells (C) were activated with immobilized anti-CD3 and anti-CD28 Abs, in the presence of IL-2 (1 ng/ml) and IL-12 (10 ng/ml).
Expression of EVER genes in the course of the activation was determined by qRT-PCR at the indicated time points. Data are representative of 3
independent experiments. D. Purified murine naive CD8+ T cells were incubated in medium or activated by anti-CD3 (CD3), anti-CD28 (CD28) or by a
combination of anti-CD3 and anti-CD28 (CD3/CD28) Abs. After 24 h, the expression of EVER1 and EVER2 was determined by qRT-PCR. Freshly purified
naive CD8+ T cells (ex vivo) were used as the reference 100% value. Data are from 3 independent experiments. E. Purified naive TCR-transgenic CD8+
T cells were activated by their cognate HA512–520 peptide in the presence of irradiated T cell-depleted syngeneic splenocytes as antigen-presenting
cells. At the indicated time points, CD8+ T cells recovered by MACS purification, and expression of EVER1 and EVER2 in these cells was determined by
qRT-PCR. Data are representative of 3 independent experiments.
doi:10.1371/journal.pone.0039995.g002
EVER Gene Expression in T-Cells
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39995activation (Fig. 3C, D), and maintained at this level for at least
72 h (data not shown). The mechanism and functional significance
of such an accumulation remain uncertain given the very limited
knowledge on the physiological role of free Zn
2+ ions in T cells.
However, this zinc accumulation could be related to the massive
changes in lymphocyte volume (about 10 times, based on the
changes of the forward side scatter in flow cytometry) and
metabolic activity during blast formation. Thus, at least two non-
mutually exclusive hypotheses could be formulated. First, zinc
accumulation could be a response to the increased needs of this
metal for the newly synthesized zinc-binding proteins. Second, it
might constitute a compensatory mechanism in order to maintain
a constant free Zn
2+ ion concentration during the massive
enlargement of the stimulated T cells.
Recentfindings, showingthatZn
2+ionsplayanimportantrolein
signal transduction and can even serve as a classical second
messenger [32–34], highlight the need for tight control of the
intracellular free zinc pool. Indeed, we observed that the aforemen-
tionedmodulationinzinctransporterexpressioninactivatedCD4+
and CD8+ T cellsis accompanied bymassive transcription ofMT-2
(Fig. 3E, F), encoding for the major zinc-buffering metallothionein
[35,36].Finally,despitetheincreaseinthetotalzinccontentpercell
following TCR/CD28 triggering (Fig. 3C, D), the intracellular
concentration of free zinc remained remarkably stable (Fig. 3G). In
this context, it is tempting to speculate that the lack of either EVER
proteinscoulddisrupttheEVER/ZnT-1complexandconsequently
impose zinc imbalance in T cells as previously demonstrated in
keratinocytes [11]. To assess the impact of the EVER-deficiency on
zinc homeostasis in lymphocytes, we first measured the concentra-
tions of free Zn
2+ in EBV-transformed B cells from an EV patient
(EVER1 Del275A) and from a healthy relative using FluoZin-3, a
zinc ion-specific fluorescent probe, and a flow cytometric assay. In
five independent measurements, the zinc concentration was higher
in EVER-deficient than in control cell lines (Fig. 4A). These results
suggest that EVERs could be involved in the regulation of cellular
zinc homeostasis.
To then address the contribution of EVER proteins for zinc
balance in primary lymphocytes, untransformed T cell lines were
generated from PBMC of two healthy individuals and two
patients, one with full-blown EV with homozygous EVER2
T150fdX3 mutation and one heterozygous for the EVER2
T150fdX3 mutation. From a clinical point of view, this
heterozygous patient clearly presented transiently EV-like erup-
tions and was HPV3 and HPV5 positive in the lesions (see
Figure 3. Zinc homeostasis in T cells. Purified murine naive CD8+ (A) or CD4+ T cells (B) were activated with immobilized anti-CD3 and anti-CD28
Abs and expression of the ZIP10 zinc transporter and EVER1 genes was determined by qRT-PCR at the indicated time points. Data are from 3
independent experiments. Total amount of free zinc was determined in murine CD8+ (C) or CD4+ T cells (D) after 24 h incubation in standard
medium (medium), in medium supplemented with IL-2 (IL-2), or with anti-CD3/anti-CD28 Abs in the presence of IL-2 (CD3/CD28). The content of free
zinc was measured by flow cytometry with FluoZin-3, a zinc ion-specific indicator. The total amount of free zinc per cell was calculated as described in
materials and methods and normalized for the unstimulated cells (medium) values (100%). Purified naive CD8+ (E) or CD4+ T cells (F) were stimulated
by immobilized anti-CD3 and anti-CD28 Abs in the presence of IL-2 and IL-12. The expression of metallothionein 2 (MT-2) was assessed by qRT-PCR.
Data are representative of 3 independent experiments. G. Murine naive CD8+ or CD4+ T cells were activated (CD3/CD28) or not (control) by
immobilized anti-CD3 and anti-CD28 Abs for 24 h The concentration of free zinc was then measured by flow cytometry with FluoZin-3. H. Purified
murine naive CD8+ T cells were activated with immobilized anti-CD3 and anti-CD28 Abs. At the indicated time the zinc ionophore pyrithione (PY) was
added to the medium at different concentrations. Radiolabeled thymidine was added 24 hrs after initiation of the cell culture, and proliferation was
assessed on the basis of the thymidine incorporation 24 h later.
doi:10.1371/journal.pone.0039995.g003
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recently described in non-symptomatic family members of an EV
patient with heterozygous EVER2 13-nucleotide deletion [37].
These data suggest that heterozygous EVER2 mutation, and the
resulting decrease in protein expression, favors HPV5 replication.
This may explain the transient EV-like clinical presentation of this
heterozygous patient. Using the FluoZin-3 based cytometric assay,
two independent measurements of free zinc in CD4+ T cells were
performed, side-by-side for all the lines. The mean free Zn
2+
concentration in EV-derived CD4+ T cells was higher than in
CD4+ T cells from healthy donors (Fig. 4B). This higher
concentration of free zinc in EVER-deficient CD4+ T cells was
maintained following overnight incubation of the cells with a
nontoxic zinc concentration (100 mM) (Fig. 4C). Although derived
from a small number of patients, these data suggest that EVER
proteins might be involved in the control of zinc homeostasis in
lymphocytes. At least two different types of intracellular zinc
signaling occur in T cells. One happens extremely rapidly after
TCR triggering as a result of zinc transporter activity. The other
depends on transcriptional changes in expression of zinc importers
and exporters that increase the cellular zinc content in a delayed
and durable manner. In this study, we have monitored the second
type of zinc signal but it would be most interesting to assess
whether there is any impact of EVER-deficiency on the early and
focal T cell zinc fluxes upon TCR activation. Further studies on a
larger cohort of EV patients and/or on EVER knock-out mice
should help settle this issue.
Since the concentration of free Zn
2+ is tightly controlled during
lymphocyte activation (Fig. 3G) and EVER-deficiency might
increase the concentration of unbound zinc ions (Fig. 4), one
burning question relates to the biological consequence of the zinc
imbalance in T cells. During T-cell activation zinc acts at different
levels. Zn
2+ participates in the interaction between Lck and CD4
and CD8 co-receptors, stabilizes Lck dimerization, and is likely
involved in the activation of protein kinase C [38–40]. It has been
shown that Zn
2+ is released from lysosomes upon T-cell activation
[32] and that it participates to IL-2R-mediated signaling through
the regulation of ERK activity [32]. Moreover, zinc influx from
extracellular sources is induced within minutes of TCR triggering
in primary T cells, with compartmentalized high zinc concentra-
tion under the zone of the T cell/APC contact. This local increase
in cytoplasmic zinc influences proximal TCR signaling resulting in
enhanced proliferative responses to suboptimal stimuli [31]. On
the other hand, Tanaka and colleagues have reported that excess
of zinc suppresses mitogen-activated IL-2 production in lympho-
cytes [41]. Collectively, the current data indicate that Zn
2+ ions
play a clear role in signal transduction and T-cell activation, and
any deviation in free zinc concentration is likely to impair these
processes [42]. This, in turn, highlights the importance of the
system that protects the cells from the high concentration of Zn
2+
in the extra-cellular milieu. Interestingly, when we disrupted this
zinc homeostasis by incubating T cells with non-toxic concentra-
tions of a zinc ionophore (pyrithione), the CD3/CD28-dependent
proliferation was inhibited, as demonstrated by thymidine
incorporation (Fig. 3H) and CFSE dilution assay (data not shown).
Naive T cells appear more sensitive to zinc than activated T cells
(Fig. 3H), even though this inhibition is only temporary lasting
cells enter into mitosis 24 hours after exposure to pyrithione (data
not shown). The reason of the higher sensitivity to zinc of naive T
cells remains to be elucidated. It is likely that activated T cells are
more resistant to excess of zinc, since they have already
reorganized the system controlling zinc homeostasis, and notably
Figure 4. Increased cellular zinc concentration in lymphocytes from EVER2-deficient patients. A. The concentration of free zinc was
measured with FluoZin-3 in two EBV-transformed lymphoblastoid cell lines, derived from two individuals from the same family. The healthy subject
carried wild-type copies of EVER1 and EVER2 genes (healthy), and the patient suffering from Epidermodysplasia Verruciformis had a homozygous
nonsense mutation (del275A) in the EVER1 gene (EV). For each line, 5 independent experiments were performed and the relative values obtained in
each of these experiments were plotted against the mean concentration of free Zn
2+ in the control cells, taken as 100%. A bilateral paired Student’s t
test analysis indicates a p value of 0.099. B–C. Primary T cell lines were generated from two patients, one with full-blown EV and homozygous for the
EVER2 T150fdX3 mutation and one with transient EV-like clinical presentation and heterozygous for the EVER2 T150fdX3 mutation, as well as from two
unrelated healthy individuals carrying wild-type copies of EVER1 and EVER2 genes (healthy). The concentration of free zinc was measured with
FluoZin-3 in CD4+ T cells maintained in standard culture medium (B) or incubated for 18 h in medium supplemented with 100 mM of zinc (C). For
each line, 2 independent experiments were performed and the mean values for each EVER2-deficient line were plotted against the mean
concentration of free Zn
2+ in the two control lines (healthy) (100%).
doi:10.1371/journal.pone.0039995.g004
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thioneins). Taking into account the known properties of ZnT-1 as
a zinc transporter, and our observations of increased concentra-
tion of Zn
2+ in EVER-deficient lymphocytes (Fig. 4), it seems
probable that the ZnT-1/EVER complex participates in the
maintenance of low levels of free zinc in lymphocytes. It is
tempting to speculate that EVER-deficiency, by shifting zinc
homeostasis, could have an impact on T-cell activation, especially
in naive T cells, in which EVER expression is the highest.
Certainly, the clinical manifestations of EVER-deficiency suggest
that such an impact does not interfere with crucial steps of T-cell
activation, as EV patients respond normally to pathogens other
than HPV. Indeed, we did not observe any striking differences in
the rate of culture expansion during preparation of the primary T
cell lines from EV patients and healthy controls (data not shown).
In conclusion, we have demonstrated that EVER genes are
expressed at high levels in T and B cells. Their expression in T
cells is sharply decreased upon TCR/CD28 stimulation, as a part
of the global activation-dependent reorganization of the molecular
machinery controlling cellular zinc homeostasis. Indeed, the
elevated intracellular amount of free Zn
2+ ions is associated with
decreased expression of ZnT-1 and increased expression of Zip10
and Zip6 in activated T cells. The preliminary data from EV
patient-derived cell lines suggest that EVER might be involved in
maintaining a constant low level of free zinc in lymphocytes.
Altogether, these results support our previously formulated
hypothesis [4] that the natural anti-HPV barrier, of which EVER
proteins constitute an essential part, might comprise at least two
arms: keratinocytes and lymphocytes. Although still speculative,
we suggest that EVER-deficiency in T cells may contribute to
susceptibility to HPV infection, possibly in combination with
EVER-deficiency in keratinocytes. However, the exact mechanism
of the impact of EVER-deficiency on T cell function as well as the
reason for the extreme selectivity of this barrier towards HPV
remains to be elucidated.
Materials and Methods
Mice
For all experiments 8 to 12 week-old female BALB/c mice were
used. For antigen-driven T-cell activation, we used the CL4-TCR
transgenic BALB/c mice, which express a TCR specific for the
influenza virus HA512–520 peptide in the context of H2-K
d on most
CD8+ T cells [27,28]. All breeding and experimental procedures
were carried out in accordance with European Union guidelines
and were approved by the regional ethics committee NuMP/18/
26/04/04.
T Cell Purification and Culture
For T cell cultures, spleens and lymph nodes were collected and
naive CD4+ or CD8+ T cells (CD4
+ CD25
2 CD62L
+ and CD8
+
CD25
2 CD62L
+, respectively) were purified by MACS (Milteny
Biotec) according to the manufacturer’s protocol ($92% or 94%
purity, respectively). The purified naive T cells were activated by
immobilized anti-CD3 (BD Biosciences, clone 145-2C11), anti-
CD28 (BD Biosciences, clone 37.51) antibodies individually, or
combination CD3/CD28 beads were used (Dynabeads mouse
CD3/CD28 T cell expander, Invitrogen). Antigen-specific stim-
ulation was performed with CL4-TCR T cells co-cultured with
irradiated, T cell-depleted, syngeneic splenocytes loaded with the
cognate peptide. For the subsequent PCR analysis transgenic T
cells were isolated by MACS (Milteny Biotec) using biotinylated
Thy1.2 mAb (BD Pharmingen, clone 53-2.1) combined with
streptavidin microbeads (Milteny Biotec).
For human T cell cultures, PBMC were obtained from buffy
coat preparations from anonymous healthy donors, from the
Purpan university hospital blood bank (Toulouse, France). Naive
CD8+ T cells were sorted by MACS from PBMC with naive
CD8+ T cell isolation kit (Milteny Biotec). Human CD4+ T cells
(TCR+,CD4+,CD45RC
High and TCR+,CD4+,CD45RC
low) were
purified by FACS. The cells were thereafter stimulated by anti-
CD3 and anti-CD28 beads (Dynabeads human T activator CD3/
CD28, Invitrogen).
EBV-transformed Human Lymphocytes
The lines have previously been generated [9] using PBMC from
an EV suffering patient (EVER2 Del275A, B. Bouadjar, P.
Cassonnet, M. Favre, G. Orth, M. Ramoz, unpublished results)
or from healthy relatives (homozygous EVER2 wt) by transforma-
tion with EBV. The cells were cultured in standard RPMI
(Invitrogen) medium supplemented with 10% FBS (Invitrogen).
The EVER2 genotype of each of the lines was confirmed by
sequencing directly before the experiments.
Primary Human T Cell Lines
One patient presented with full-blown EV and was homozygous
for the EVER2 T150fdX3 mutation (P. Cassonnet, M. Favre, S.
Jablonska, S. Majewski, G. Orth, M. Ramoz, unpublished results).
Her daughter was heterozygous for the EVER2 T150fdX3
mutation and had developed transient EV-like symptoms. Her
first skin lesions were plane warts on the dorsum of the hands that
appeared at the age of 7 yrs. The lesions were treated successfully
by liquid nitrogen freezing. However at the age of 14 years new
extensive skin lesions developed on the dorsum of the hands and
feet, as well as on the trunk. These lesions were much more
abundant, some of them larger than typical plane warts. Some of
the lesions were confluent with uneven polycystic outlines. The
lesions persisted for about 2 years and disappeared after several
courses of cryotherapy. In the skin lesions DNA of HPV3 and
HPV5 was detected. Polyclonal T cell lines were generated from
PBMC of the 2 patients or healthy controls, as previously
described [43]. Briefly, mixed lymphocyte reaction cultures of
PBMC (5610
5 cells/ml) and irradiated allogenic PBMC from 2
different donors (10
6 cells/ml) were performed. The lines were
cultured in IMDM (Cambrex Bio Science) supplemented with
1 mg/ml PHA, and 100 IU/ml recombinant human IL-2
(Chiron), 10% YSSEL medium (Dyaclone), 5% FBS (Cambrex
Bio science), and penicillin/streptomycin (Bristol-Myers Squibb).
T cells were restimulated as described every 2 weeks. T cells were
used in this study after one stimulation cycle. The study was
approved by the Ethics Committee at the Medical University of
Warsaw. Written informed consent was received from all
participants.
RT-PCR
RNA from the cell cultures or organs was isolated by RNeasy
mini kit (Quiagen), and reverse transcription (SuperScript III first-
strand synthesis system for RT-PCR, Invitrogen) was performed,
according to the manufacturer’s instructions. The obtained cDNA
was used as a template in classical PCR (RT-PCR; Taq
Polymerase, Q-BIOgene) or in quantitative PCR (qRT-PCR;
qPCR mastermix plus for SYBRgreen, Eurogentec). The primers
used for the assessment of the EVER genes expression were
designed using primer3 software (http://frodo.wi.mit.edu/
primer3/) and their validity was confirmed by direct sequencing
of the PCR product (RT-PCR) or by the sequencing of the qRT-
PCR products cloned into the standard vector (Topo TA cloning
kit for sequencing, Invitrogen). The primers used for qRT-PCR on
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GAGCTGTTG3’, Ever1_R : 59CTCTGAGAAGGTGAGGA-
CAGC39; Ever2_F : 59GCTTCATCCGGGAACTGC39,
Ever2_R : 59AGAGGCCCCCAATCTCGTA39; Znt1_F :
59GGCCAACACCAGCAATTC39, Znt1_R :
59CTTCCGCTTCCAGATTGTCA39; MT-2_F : 59AACTCTT-
CAAACCGATCTCTCGT39, MT-2_R : 59AAGTACATTTG-
CATTGTTTGCATT39; Zip6_F: 59GATGGTGAT-
CATGGGCGAC39, Zip6_R:
59CTGTTTTGCTAAAGGCTGG39; Zip10_F : 59GAGCGGA-
GAGGAGATGCAC39, Zip10_R : 59TCCCACGAT-
GATGTCTGTGA39; HPRT_F : 59TGACACTGGTAAAA-
CAATGCAAACT39, HPRT_R :
59AACAAAGTCTGGCCTGTATCCAA39. The primers used
for qRT-PCR on human cells were Ever1_F :
59GTGGCCTGCCCTACAACAT39, Ever1_R : 59CCGAAA-
GAGTGAGCCATGC39; Ever2_F : 59CAAGAAGTA-
CACCCTCCTGAAGA39, Ever2_B : 59GAGGAGTG-
GATGCTGCTGAC39; GAPDH_F :
59ACGGATTTGGTCGTATTGGGC39, GAPDH_B :
59TTGACGGTGCCATGGAATTTG39.
Transfections
293 T cells were cultured in DMEM medium (Invitrogen)
supplemented with 10% FBS. They were transfected with plasmid
encoding EVER1-FLAG or EVER2- FLAG fusion protein using
FuGENE-6 (Roche), according to the manufacturer’s instructions.
The cells were cultured for 24 h before analysis of EVER protein
expression.
Western Blot Analysis
Primary T cells or transfected 293 cells were lysed using RIPA
buffer (10 mM Tris HCL ph 7,5, 50 mM NaCl, 1% Triton X100,
30 mM Na4P2O7,5 mM ZnCl2, 10% Glycerol, 0,1% SDS,
50 mM NaF, 1 nM Na3VO4, 1 mM DTT, and Roche mini
complete protease inhibitor). The crude lysates (or precipitated
proteins, depending on the experiment) were migrated on 10%
polyacrylamide gels (Novex, Invitrogen) and transferred onto
nitrocellulose membranes (Amersham Biosciences). The following
primary antibodies were used: polyclonal Ab anti-EVER1
(Osenses ref: OSR00223W), polyclonal Ab anti-EVER1 (Abcam
ref: ab67326), anti-ß-actin (Sigma, clone AC-15) and anti-FLAG
(Sigma, clone M2). The following secondary antibodies were used
anti-rabbit (Li-Cor Biosciences ref 926-32211) and anti-mouse (Li-
Cor Biosciences ref: 926-32220) labeled with DyLight fluor dyes
(IR DYE 800 and IR DYE 680, respectively) and the signal was
detected using the LI-COR Odyssey Infrared Imaging System (LI-
COR Biosciences).
For the precipitation of EVER1-FLAG and EVER2-FLAG
proteins, we employed the standard immunoprecipitation method
with the anti-FLAG antibody and Protein G PLUS agarose (Santa
Cruz Biotechnology, ref: sc2002).
Free Zinc Concentration Measurements
Free zinc concentration in lymphocytes was measured by flow
cytometry as previously described [44]. Briefly, the cells were
loaded for 30 min. with FluoZin-3 (Invitrogen, ref: F-24195), a
zinc ion-specific fluorescent probe. Each experiment contained 3
samples: the ‘‘minimum’’ control, the ‘‘maximum’’ control and the
experimental sample. The ‘‘minimum’’ control cells were subse-
quently incubated with zinc chelator (TPEN; 100 mM - Sigma –
ref: 87641). The ‘‘maximum’’ control cells with zinc ionophore
(pyrithione; 50 mM - Sigma– ref: 63844) and 100 mM ZnSO4
(Sigma, ref: Z-0251). The zinc concentration was calculated on the
basis of the median fluorescence intensity, according to a
previously published formula [43]. The changes in the total
cellular free zinc content during T-cell activation was assessed by
taking into account the changes in the zinc concentration and the
modifications of the mean cell volume (estimated according to the
formula: VD=(FSC1)
34(FSC2)
36100%, where VD is a mean
volume change in the time and FSC1 and FSC2 are forward side
scatter values measure at two different time points).
H
3-thymidine Incorporation Assay
Purified murine naive CD8+ T cells were seeded in 96-well
plates and stimulated using anti-CD3 and anti-CD28 beads
(Dynabeads mouse CD3/CD28 T cell expander, Invitrogen). At
the start of the culture or after 3, 6 or 24 h of stimulation, the zinc
ionophore (pyrithione, Sigma, ref: 63844) was added at the
indicated concentrations. After 24 h, H
3-thymidine was added
followed by 18 h incubation. Cell associated radioactivity was
measured with a Beta counter (PerkinElmer, 1450 LSC &
Luminescence counter, MicroBeta Trilux).
Supporting Information
Figure S1 Expression of EVER1 and EVER2 in human T
cells. Expression of EVER1 and EVER2 genes was assessed in
freshly MACS-purified human CD4+ or CD8+ T cells by (A)
conventional RT-PCR (2 independent experiments) or (B) qRT-
PCR (3 independent experiments).
(TIF)
Figure S2 EVER1 and EVER2 expression is strongly
down-regulated in human T cells following TCR-medi-
ated activation. Freshly purified human naive CD8+ (A) or
CD4+ T cells (B) were activated with immobilized anti-CD3 and
anti-CD28 Abs. Expression of EVER genes was determined by
qRT-PCR at the indicated time points in the course of activation.
Data are from 3 independent experiments.
(TIF)
Figure S3 ZIP6 zinc transporter expression is up-
regulated in T cells following TCR-mediated activation.
Purified murine naive CD8+ (A) or CD4+ T cells (B) were
activated with immobilized anti-CD3 and anti-CD28 Abs and
expression of the ZIP6 zinc transporter, EVER1 and EVER2 genes
was determined by qRT-PCR at the indicated time points. Data
are from 3 independent experiments.
(TIF)
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